Sun Pharmaceuticals has emerged as a key speciality player, with global speciality revenues rising from 7% in FY18 to 18% in ...

BTIG analyst Mark Massaro lowered the firm’s price target on NeoGenomics (NEO) to $18 from $21 and keeps a Buy rating on the shares. The stock ...

Whether you’re a fan of the All Blacks, a follower of the women’s game or someone who watches every phase of play in the Premiership, our rugby features and news pieces will provide you with all of ...